ClinicalTrials.gg
CompletedNCT02880475Updated Jul 17, 2019Results posted

OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients

A Phase 1 interventional study of OXN PR tablet in Chronic Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-17.

Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2014, registered Jul 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.

Enrollment
29th of 34
30 · median 80
Started
2014
with 1 other
Phase 1
8 of 43
none open now
Registered
5th of 43
by date
Lead sponsor
5 of 43
Mundipharma (China) Pharmaceutical Co. Ltd

Among the 43 studies in Chronic Pain with a site in China, this one is the 29th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2014, is one of 8 in phase 1, and was the 5th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Chronic Pain with a site in China, or all of them as a file.
02

Study summary

This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10 mg (OXN 20/10) in Chinese patients with moderate to severe chronic non-malignant pain.

Read the detailed description

It will be conducted to assess the pharmacokinetics of OXN 5/2.5 and OXN 20/10 tablets. Subjects will be allocated to a sequence of two strength group in accordance with a random allocation schedule (RAS) in a 1:1 ratio.

Subjects will attend a screening visit within 14 days of the first (OXN) dosing day (Day 1).

Eligible subjects will then check into the study unit on the day before OXN dosing (Day -2). Subjects will be administered their OXN dose the next 2 morning (Day 1), following an overnight fast.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Moderate to severe chronic non-malignant pain
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult Chinese patients with moderate to severe chronic non-malignant pain.
  2. Male and female subjects with age range 18 to 65 years (including 18 and 65), body weight ≥ 45kg and range 18 to 30 (including 18 and 30).
  3. Patients who should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale.
  4. Patients, who are able to read, understand and sign written prior to study participation and are willing to follow the protocol requirements.
  5. Females of and less than one year must have a negative serum pregnancy test during screening visit and at check-in and be non-lactating. In addition, they must be willing to use adequate and reliable throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectables, combined oral contraceptives, some IUDs (intrauterine Device, hormonal), sexual abstinence or vasectomised partner.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant (positive β-human chorionic gonadotrophin [HCG] test) or lactating.
  2. Use of opioid or opioid antagonist-containing medication in the 30 days before the start of the study.
  3. Known sensitivity to oxycodone, naloxone, or related compounds.
  4. Subjects with clinically unstable respiratory disease, dysfunction of the biliary tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy requiring intervention (medication or surgical) or renal artery stenosis, or any other medical condition, that, in the opinion of the investigator or the sub-investigator, precludes entry into this study.
  5. Subject who have a past (within 5 years) history of malignant neoplasm including leukemia and lymphoma.
  6. The examination results are abnormal, in the opinion of the investigator or the sub-investigator, and are clinical significance.
  7. Subjects with abnormal liver function (values exceed the for , ALT or total during the Screening Period) or abnormal renal function (values exceed the upper limit of normal for serum creatinine during the Screening Period).
  8. Patients with a to the study medication.
  9. Subjects who have a psychiatric disorder such that participation in the study may, in the opinion of the investigator or the sub-investigator, pose an unacceptable risk to the subject.
  10. Subjects who have a current or past (within 5 years) history of substance or alcohol abuse, or subjects who give a positive result in drug abuse test during the Screening Period, or subjects who, in the opinion of the investigator or the sub-investigator, have demonstrated addictive or substance abuse behaviors.
  11. Subjects with uncontrolled seizures or convulsive disorder.
  12. Subjects who will receive any interventional therapy (surgery, paracentesis,etc) for arthritis during the study period.
  13. History of or any current conditions that might have interfered with drug absorption, distribution, metabolism or excretion.
  14. Any history of frequent nausea or emesis regardless of aetiology.
  15. Participation in any clinical drug study during the 3 months preceding the initial dose in this study.
  16. Use of any medication including vitamins, herbal and/or mineral supplements during the course of the study, other than Vitamin D, calcium supplements and continued use by females of medication or HRT.
  17. Consumption of alcoholic beverages within 48 hours before study drug administration, and refusal to abstain from alcohol until at least 48 hours after the last study drug administration.
  18. Blood or blood products donated within 90 days prior to study drug administration or anytime during the study, except as required by this protocol.
  19. Positive results of urine drug screen(for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids), alcohol breath test, surface antigen (HBsAg), virus antibody (Ab), (HIV) test or qualitative syphilis tests.
  20. Patients with moderate to severe hypohemia (HGB\<90g/L during the screening).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    OXN prolonged release tablet 5/2.5mg

    The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.

    Drug: OXN PR tablet

  • Experimental
    OXN prolonged release tablet 20/10mg

    The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.

    Drug: OXN PR tablet

Interventions

  • Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg

    Also known as: Targin

06

What researchers measure

Primary outcomes

  1. AUC0-48hr of Noroxycodone Plasma Concentration.

    AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.

  2. AUC0-t of Noroxycodone Plasma Concentration

    AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf \< 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.

  3. AUC_%Extrap of Noroxycodone Plasma Concentration

    AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  4. AUCinf of Noroxycodone Plasma Concentration

    AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  5. Cmax of Noroxycodone Plasma Concentration

    Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  6. Lambda_z of Noroxycodone Plasma Concentration

    Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  7. T1/2 of Noroxycodone Plasma Concentration

    T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  8. Tmax of Noroxycodone Plasma Concentration

    Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  9. AUC0-48hr of Noroxymorphone Plasma Concentration

    AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  10. AUC0-t of Noroxymorphone Plasma Concentration

    AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  11. AUC_%Extrap of Noroxymorphone Plasma Concentration

    AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  12. AUCinf of Noroxymorphone Plasma Concentration

    AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  13. Cmax of Noroxymorphone Plasma Concentration

    Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  14. Lambda_z of Noroxymorphone Plasma Concentration

    Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  15. T1/2 of Noroxymorphone Plasma Concentration

    T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  16. Tmax of Noroxymorphone Plasma Concentration

    Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  17. AUC0-48hr of Oxycodone Plasma Concentration

    AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  18. AUC0-t of Oxycodone Plasma Concentration

    AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  19. AUC_%Extrap of Oxycodone Plasma Concentration

    AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  20. AUCinf of Oxycodone Plasma Concentration

    AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  21. Cmax of Oxycodone Plasma Concentration

    Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  22. Lambda_z of Oxycodone Plasma Concentration

    Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  23. T1/2 of Oxycodone Plasma Concentration

    T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  24. Tmax of Oxycodone Plasma Concentration

    Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  25. AUC0-48hr of Oxymorphone Plasma Concentration

    AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  26. AUC0-t of Oxymorphone Plasma Concentration

    AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  27. AUC_%Extrap of Oxymorphone Plasma Concentration

    AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  28. AUCinf of Oxymorphone Plasma Concentration

    AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  29. Cmax of Oxymorphone Plasma Concentration

    Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  30. Lambda_z of Oxymorphone Plasma Concentration

    Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  31. T1/2 of Oxymorphone Plasma Concentration

    T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  32. Tmax of Oxymorphone Plasma Concentration

    Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  33. AUC0-48hr of 6-B-Naloxol Plasma Concentration

    AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  34. AUC0-t of 6-B-Naloxol Plasma Concentration

    AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  35. AUC_%Extrap of 6-B-Naloxol Plasma Concentration

    AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  36. AUCinf of 6-B-Naloxol Plasma Concentration

    AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  37. Cmax of 6-B-Naloxol Plasma Concentration

    Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  38. Lambda_z of 6-B-Naloxol Plasma Concentration

    Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  39. T1/2 of 6-B-Naloxol Plasma Concentration

    T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  40. Tmax of 6-B-Naloxol Plasma Concentration

    Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  41. AUC0-48hr of NLLG Plasma Concentration

    AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  42. AUC0-t of NLLG Plasma Concentration

    AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  43. AUC_%Extrap of NLLG Plasma Concentration

    AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  44. AUCinf of NLLG Plasma Concentration

    AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  45. Cmax of NLLG Plasma Concentration

    Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  46. Lambda_z of NLLG Plasma Concentration

    Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  47. T1/2 of NLLG Plasma Concentration

    T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  48. Tmax of NLLG Plasma Concentration

    Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  49. AUC0-48hr of NLXG Plasma Concentration

    AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  50. AUC0-t of NLXG Plasma Concentration

    AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  51. AUC_%Extrap of NLXG Plasma Concentration

    AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  52. AUCinf of NLXG Plasma Concentration

    AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  53. Cmax of NLXG Plasma Concentration

    Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  54. Lambda_z of NLXG Plasma Concentration

    Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  55. T1/2 of NLXG Plasma Concentration

    T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  56. Tmax of NLXG Plasma Concentration

    Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  57. AUC0-48hr of Naloxone Plasma Concentration

    AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  58. AUC0-t of Naloxone Plasma Concentration

    AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  59. AUC_%Extrap of Naloxone Plasma Concentration

    AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  60. AUCinf of Naloxone Plasma Concentration

    AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  61. Cmax of Naloxone Plasma Concentration

    Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  62. Lambda_z of Naloxone Plasma Concentration

    Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  63. T1/2 of Naloxone Plasma Concentration

    T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

  64. Tmax of Naloxone Plasma Concentration

    Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

    Time frame: Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

07

Results

Posted Jul 17, 2019

Participant flow

Participant flow — Overall Study
MilestoneOXN Prolonged Release Tablet 5/2.5 mgOXN Prolonged Release Tablet 20/10 mg
Started1317
Completed1317
Not completed00

Outcome measures

PrimaryAUC0-48hr of Noroxycodone Plasma Concentration.

AUC0-48hr of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-48hr of Noroxycodone Plasma Concentration.
hr*ng/mLOXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mg
AUC0-48hr of Noroxycodone Plasma Concentration.81.72 ± 39.82325.51 ± 99.47
PrimaryAUC0-t of Noroxycodone Plasma Concentration

AUC0-t of Noroxycodone plasma concentration.Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg will be analyzed .(If the extrapolated area of AUC is larger than 20% of AUCinf, i.e. AUC0-t/AUCinf \< 0.8, then the elimination-related PK parameters (AUCinf, T1/2, Lambda_z) will not be adopted and will not be included in any statistical analysis. )

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-t of Noroxycodone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of Noroxycodone Plasma Concentration81.25 ± 40.27325.37 ± 99.76
PrimaryAUC_%Extrap of Noroxycodone Plasma Concentration

AUC_%Extrap of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of Noroxycodone Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of Noroxycodone Plasma Concentration2.99 ± 1.171.45 ± 0.67
PrimaryAUCinf of Noroxycodone Plasma Concentration

AUCinf of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUCinf of Noroxycodone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUCinf of Noroxycodone Plasma Concentration83.74 ± 41.66330.44 ± 102.51
PrimaryCmax of Noroxycodone Plasma Concentration

Cmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · ng/mL
Cmax of Noroxycodone Plasma Concentration
ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of Noroxycodone Plasma Concentration4.68 ± 1.5320.69 ± 3.88
PrimaryLambda_z of Noroxycodone Plasma Concentration

Lambda_z of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · 1/hr
Lambda_z of Noroxycodone Plasma Concentration
1/hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Lambda_z of Noroxycodone Plasma Concentration0.10 ± 0.020.10 ± 0.01
PrimaryT1/2 of Noroxycodone Plasma Concentration

T1/2 of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr
T1/2 of Noroxycodone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
T1/2 of Noroxycodone Plasma Concentration7.42 ± 1.427.16 ± 1.02
PrimaryTmax of Noroxycodone Plasma Concentration

Tmax of Noroxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of Noroxycodone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of Noroxycodone Plasma Concentration4.50 (1.50 to 8.02)4.00 (2.50 to 5.02)
PrimaryAUC0-48hr of Noroxymorphone Plasma Concentration

AUC0-48hr of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-48hr of Noroxymorphone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of Noroxymorphone Plasma Concentration14.10 ± 5.0265.84 ± 25.50
PrimaryAUC0-t of Noroxymorphone Plasma Concentration

AUC0-t of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-t of Noroxymorphone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of Noroxymorphone Plasma Concentration12.92 ± 5.2165.65 ± 25.78
PrimaryAUC_%Extrap of Noroxymorphone Plasma Concentration

AUC_%Extrap of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of Noroxymorphone Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of Noroxymorphone Plasma Concentration14.89 ± 11.614.25 ± 1.98
PrimaryAUCinf of Noroxymorphone Plasma Concentration

AUCinf of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUCinf of Noroxymorphone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUCinf of Noroxymorphone Plasma Concentration15.76 ± 4.6868.17 ± 26.22
PrimaryCmax of Noroxymorphone Plasma Concentration

Cmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · ng/mL
Cmax of Noroxymorphone Plasma Concentration
ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of Noroxymorphone Plasma Concentration0.75 ± 0.293.54 ± 1.64
PrimaryLambda_z of Noroxymorphone Plasma Concentration

Lambda_z of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · 1/hr
Lambda_z of Noroxymorphone Plasma Concentration
1/hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Lambda_z of Noroxymorphone Plasma Concentration0.08 ± 0.020.08 ± 0.01
PrimaryT1/2 of Noroxymorphone Plasma Concentration

T1/2 of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr
T1/2 of Noroxymorphone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
T1/2 of Noroxymorphone Plasma Concentration8.55 ± 1.539.08 ± 1.42
PrimaryTmax of Noroxymorphone Plasma Concentration

Tmax of Noroxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of Noroxymorphone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of Noroxymorphone Plasma Concentration7.00 (2.00 to 10.00)5.00 (2.50 to 7.00)
PrimaryAUC0-48hr of Oxycodone Plasma Concentration

AUC0-48hr of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-48hr of Oxycodone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of Oxycodone Plasma Concentration89.48 ± 34.38272.11 ± 48.51
PrimaryAUC0-t of Oxycodone Plasma Concentration

AUC0-t of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-t of Oxycodone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of Oxycodone Plasma Concentration88.45 ± 34.55271.21 ± 48.79
PrimaryAUC_%Extrap of Oxycodone Plasma Concentration

AUC_%Extrap of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of Oxycodone Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of Oxycodone Plasma Concentration1.78 ± 1.150.57 ± 0.21
PrimaryAUCinf of Oxycodone Plasma Concentration

AUCinf of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUCinf of Oxycodone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUCinf of Oxycodone Plasma Concentration89.85 ± 34.72272.71 ± 48.77
PrimaryCmax of Oxycodone Plasma Concentration

Cmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · ng/mL
Cmax of Oxycodone Plasma Concentration
ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of Oxycodone Plasma Concentration6.69 ± 1.6724.64 ± 6.30
PrimaryLambda_z of Oxycodone Plasma Concentration

Lambda_z of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · 1/hr
Lambda_z of Oxycodone Plasma Concentration
1/hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Lambda_z of Oxycodone Plasma Concentration0.14 ± 0.040.14 ± 0.02
PrimaryT1/2 of Oxycodone Plasma Concentration

T1/2 of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr
T1/2 of Oxycodone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
T1/2 of Oxycodone Plasma Concentration5.09 ± 0.965.03 ± 0.69
PrimaryTmax of Oxycodone Plasma Concentration

Tmax of Oxycodone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of Oxycodone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of Oxycodone Plasma Concentration3.75 (1.02 to 8.00)2.00 (0.50 to 5.00)
PrimaryAUC0-48hr of Oxymorphone Plasma Concentration

AUC0-48hr of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-48hr of Oxymorphone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of Oxymorphone Plasma Concentration3.70 ± 1.333.59 ± 0.97
PrimaryAUC0-t of Oxymorphone Plasma Concentration

AUC0-t of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*ng/mL
AUC0-t of Oxymorphone Plasma Concentration
hr*ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of Oxymorphone Plasma Concentration0.14 ± 0.331.66 ± 1.21
PrimaryAUC_%Extrap of Oxymorphone Plasma Concentration

AUC_%Extrap of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of Oxymorphone Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of Oxymorphone Plasma Concentration82.85 ± 21.5151.11 ± 26.70
PrimaryAUCinf of Oxymorphone Plasma Concentration

AUCinf of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

No measurements were reported for this outcome.

PrimaryCmax of Oxymorphone Plasma Concentration

Cmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · ng/mL
Cmax of Oxymorphone Plasma Concentration
ng/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of Oxymorphone Plasma Concentration0.03 ± 0.060.30 ± 0.17
PrimaryLambda_z of Oxymorphone Plasma Concentration

Lambda_z of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

No measurements were reported for this outcome.

PrimaryT1/2 of Oxymorphone Plasma Concentration

T1/2 of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

No measurements were reported for this outcome.

PrimaryTmax of Oxymorphone Plasma Concentration

Tmax of Oxymorphone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of Oxymorphone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of Oxymorphone Plasma Concentration0.75 (0.50 to 1.00)1.75 (0.50 to 5.00)
PrimaryAUC0-48hr of 6-B-Naloxol Plasma Concentration

AUC0-48hr of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-48hr of 6-B-Naloxol Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of 6-B-Naloxol Plasma Concentration1655.48 ± 667.025065.33 ± 3358.14
PrimaryAUC0-t of 6-B-Naloxol Plasma Concentration

AUC0-t of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-t of 6-B-Naloxol Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of 6-B-Naloxol Plasma Concentration1373.11 ± 779.635049.62 ± 3374.52
PrimaryAUC_%Extrap of 6-B-Naloxol Plasma Concentration

AUC_%Extrap of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of 6-B-Naloxol Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of 6-B-Naloxol Plasma Concentration21.24 ± 15.9833.37 ± 15.60
PrimaryAUCinf of 6-B-Naloxol Plasma Concentration

AUCinf of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUCinf of 6-B-Naloxol Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUCinf of 6-B-Naloxol Plasma Concentration1828.39 ± 878.66—
PrimaryCmax of 6-B-Naloxol Plasma Concentration

Cmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · pg/mL
Cmax of 6-B-Naloxol Plasma Concentration
pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of 6-B-Naloxol Plasma Concentration85.18 ± 47.25269.53 ± 189.50
PrimaryLambda_z of 6-B-Naloxol Plasma Concentration

Lambda_z of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · 1/hr
Lambda_z of 6-B-Naloxol Plasma Concentration
1/hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Lambda_z of 6-B-Naloxol Plasma Concentration0.07 ± 0.02—
PrimaryT1/2 of 6-B-Naloxol Plasma Concentration

T1/2 of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr
T1/2 of 6-B-Naloxol Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
T1/2 of 6-B-Naloxol Plasma Concentration9.78 ± 2.20—
PrimaryTmax of 6-B-Naloxol Plasma Concentration

Tmax of 6-B-Naloxol plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of 6-B-Naloxol Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of 6-B-Naloxol Plasma Concentration6.50 (0.50 to 14.00)1.75 (0.50 to 12.00)
PrimaryAUC0-48hr of NLLG Plasma Concentration

AUC0-48hr of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-48hr of NLLG Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of NLLG Plasma Concentration57735.72 ± 24399.37209514.4 ± 104345.5
PrimaryAUC0-t of NLLG Plasma Concentration

AUC0-t of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-t of NLLG Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of NLLG Plasma Concentration57737.49 ± 24400.80209514.4 ± 104345.5
PrimaryAUC_%Extrap of NLLG Plasma Concentration

AUC_%Extrap of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of NLLG Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of NLLG Plasma Concentration13.13 ± 14.0920.07 ± 9.23
PrimaryAUCinf of NLLG Plasma Concentration

AUCinf of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUCinf of NLLG Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUCinf of NLLG Plasma Concentration62953.71 ± 26257.03—
PrimaryCmax of NLLG Plasma Concentration

Cmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · pg/mL
Cmax of NLLG Plasma Concentration
pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of NLLG Plasma Concentration3442.63 ± 1800.1711372.74 ± 5426.77
PrimaryLambda_z of NLLG Plasma Concentration

Lambda_z of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · 1/hr
Lambda_z of NLLG Plasma Concentration
1/hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Lambda_z of NLLG Plasma Concentration0.07 ± 0.02—
PrimaryT1/2 of NLLG Plasma Concentration

T1/2 of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr
T1/2 of NLLG Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
T1/2 of NLLG Plasma Concentration11.32 ± 4.26—
PrimaryTmax of NLLG Plasma Concentration

Tmax of NLLG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of NLLG Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of NLLG Plasma Concentration11.00 (0.50 to 14.00)1.50 (0.50 to 7.00)
PrimaryAUC0-48hr of NLXG Plasma Concentration

AUC0-48hr of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-48hr of NLXG Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of NLXG Plasma Concentration78725.81 ± 28285.24320734.4 ± 113332.8
PrimaryAUC0-t of NLXG Plasma Concentration

AUC0-t of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-t of NLXG Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of NLXG Plasma Concentration77976.24 ± 28477.82320734.4 ± 113332.8
PrimaryAUC_%Extrap of NLXG Plasma Concentration

AUC_%Extrap of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of NLXG Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of NLXG Plasma Concentration1.56 ± 1.051.86 ± 1.39
PrimaryAUCinf of NLXG Plasma Concentration

AUCinf of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUCinf of NLXG Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUCinf of NLXG Plasma Concentration79025.78 ± 28389.19326907.3 ± 115103.6
PrimaryCmax of NLXG Plasma Concentration

Cmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · pg/mL
Cmax of NLXG Plasma Concentration
pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of NLXG Plasma Concentration11488.62 ± 2493.4845789.83 ± 10576.00
PrimaryLambda_z of NLXG Plasma Concentration

Lambda_z of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · 1/hr
Lambda_z of NLXG Plasma Concentration
1/hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Lambda_z of NLXG Plasma Concentration0.14 ± 0.030.09 ± 0.03
PrimaryT1/2 of NLXG Plasma Concentration

T1/2 of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr
T1/2 of NLXG Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
T1/2 of NLXG Plasma Concentration5.28 ± 1.358.40 ± 2.43
PrimaryTmax of NLXG Plasma Concentration

Tmax of NLXG plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of NLXG Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of NLXG Plasma Concentration1.01 (0.50 to 8.00)1.25 (0.50 to 3.00)
PrimaryAUC0-48hr of Naloxone Plasma Concentration

AUC0-48hr of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-48hr of Naloxone Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-48hr of Naloxone Plasma Concentration281.91 ± 122.61650.42 ± 222.44
PrimaryAUC0-t of Naloxone Plasma Concentration

AUC0-t of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · hr*pg/mL
AUC0-t of Naloxone Plasma Concentration
hr*pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC0-t of Naloxone Plasma Concentration136.17 ± 92.95443.88 ± 252.95
PrimaryAUC_%Extrap of Naloxone Plasma Concentration

AUC_%Extrap of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · (%)
AUC_%Extrap of Naloxone Plasma Concentration
(%)OXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
AUC_%Extrap of Naloxone Plasma Concentration47.82 ± 20.9544.94 ± 26.95
PrimaryAUCinf of Naloxone Plasma Concentration

AUCinf of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

No measurements were reported for this outcome.

PrimaryCmax of Naloxone Plasma Concentration

Cmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Mean · pg/mL
Cmax of Naloxone Plasma Concentration
pg/mLOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Cmax of Naloxone Plasma Concentration33.21 ± 24.6245.10 ± 21.03
PrimaryLambda_z of Naloxone Plasma Concentration

Lambda_z of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

No measurements were reported for this outcome.

PrimaryT1/2 of Naloxone Plasma Concentration

T1/2 of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.

No measurements were reported for this outcome.

PrimaryTmax of Naloxone Plasma Concentration

Tmax of Naloxone plasma concentration. Plasma concentrations of OXN 5/2.5 mg and OXN 20/10mg Will be Analyzed.

Time frame:
Pre-dose, 0.5h, 1.0h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 24h, 28h, 32h, 36h, and 48h Post Dose blood sampling to determine the PK of oxycodone, naloxone and metabolites in Chinese patients.
Reported as:
Median · hr
Tmax of Naloxone Plasma Concentration
hrOXN Prolonged Release Tablet 5/2.5mgOXN Prolonged Release Tablet 20/10mg
Tmax of Naloxone Plasma Concentration8.00 (5.00 to 14.00)1.00 (0.50 to 8.00)

Adverse events

Collected over Events will be recorded from the point at which the Informed Consent is signed until 7(+3) days after the subject leaves the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OXN PR Tablet 5/2.5 mg0/13 (0%)1/13 (7.7%)9/13 (69.2%)
OXN PR Tablet 20/10 mg0/17 (0%)0/17 (0%)13/17 (76.5%)
Most frequent serious events
Most frequent serious events
EventOXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mg
upper respiratory tract infectionInfections and infestations1/130/17
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mg
SleepinessNervous system disorders4/136/17
dizzinessNervous system disorders2/135/17
nauseaGastrointestinal disorders0/135/17
vomitGastrointestinal disorders1/135/17
headacheNervous system disorders3/131/17
Difficult defecationGastrointestinal disorders3/133/17
HypertriglyceridemiaMetabolism and nutrition disorders2/131/17
dry pharynxRespiratory, thoracic and mediastinal disorders0/132/17
abdominal distensionGastrointestinal disorders1/132/17
upper respiratory tract infectionInfections and infestations1/131/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mgTotal
<=18 years000
Between 18 and 65 years131730
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)OXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mgTotal
Female7815
Male6915
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)OXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mgTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)OXN PR Tablet 5/2.5 mgOXN PR Tablet 20/10 mgTotal
China131730
08

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jun 2015, 12 months.

Results were first posted in Jul 2019, 4 years 1 month after primary completion.

Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.

Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2016
First posted
Aug 26, 2016
StartActual
Jun 1, 2014
Primary completionActual
Jun 1, 2015
CompletionActual
Jul 10, 2015
Results first posted
Jul 17, 2019
Last update
Jul 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02880475
Responsible party
Sponsor
First posted
Aug 26, 2016
Start date
Jun 1, 2014
Primary completion
Jun 1, 2015
Completion
Jul 10, 2015
Results posted
Jul 17, 2019
Last update
Jul 17, 2019

Study contacts

Victoria YU
study director · Mundipharma (China) Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone naloxone combination

Start the discussion